Skip to content

A Clinical Trial to Evaluate the Sensitivity and Specificity of WAYMED Endo Compared to the Endoscopists in Classifying Early Gastric Cancer (EGC) Based on the Depth of Invasion in Endoscopic Images

A Retrospective, Single Center, Double Arm, Blind, Controlled, Pivotal Trial to Evaluate Classification by the Depth of Invasion of Early Gastric Cancer Sensitivity and Specificity of Gastric Cancer Image Computer Aided Detection and Diagnosis Software 'WAYMED Endo' and Endoscopists in Endoscopic Images

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06317103
Enrollment
653
Registered
2024-03-19
Start date
2023-08-22
Completion date
2023-08-22
Last updated
2024-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Gastric Cancer

Keywords

The depth of invasion categories for EGC (mucosal invasion, submucosal invasion)

Brief summary

The purpose of this clinical trial is to prove that the prediction capability of 'WAYMED endo' is superior to that of the endoscopists in classifying EGC based on the depth of invasion categories in gastro-endoscopic images. The computer-aided detection·diagnosis software is an Artificial Intelligence (AI) software used to assist medical specialists in diagnostic decisions by automatically classifying EGC based on the depth of invasion categories in gastro-endoscopic images and displaying the results and possibilities on the User Interface (UI).

Detailed description

This clinical trial aims to evaluate the sensitivity and specificity of 'WAYMED endo' compared to that of endoscopists in classifying EGC based on the depth of invasion categories in gastro-endoscopic images. It is designed as a retrospective, single-center, double-arm, double-blind (endoscopist, investigational medical device applicator), controlled, and pivotal trial. Medical data collected retrospectively from subjects who underwent Esophagogastroduodenoscopy (EGD) and biopsy are screened. As a result of screening, medical data that meet all inclusion/exclusion criteria are enrolled and assigned to the trial and control groups. In the trial group, the investigational medical device is applied to the images, while the endoscopists interpret the images in the control group. The Reference Standard Establishment Committee records the reference standard results as either Mucosa (mucosal invasion) or Submucosa (submucosal invasion), based on the depth of invasion of the lesion, and marks the detected lesion area with an oval on the image. The reference standard results are blinded, so they cannot be disclosed to the endoscopists or the investigational medical device applicator. The primary endpoint includes the sensitivity (%) and specificity (%) of WAYMED endo and the endoscopists in classifying EGC based on the depth of invasion categories (Mucosa or Submucosa) as confirmed by the reference standard. The secondary endpoint includes the accuracy (%) of WAYMED endo and the endoscopists in accurately classifying all early gastric cancer images as either Mucosa or Submucosa, based on the depth of invasion categories as confirmed through pathological examination.

Interventions

OTHERControl group (the endoscopists)

Interpretation of the gastro-endoscopic images as Mucosa or Submucosa by the endoscopists

DEVICEWADYMED endo

Classification of the gastro-endoscopic images as Mucosa or Submucosa by WADYMED endo (Gastric cancer image, computer aided detection/diagnosis software)

Sponsors

WAYCEN Inc
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1\. Patients aged 19 years or older who underwent EGD 2. Confirmed the presence of gastric cancer through the Electronic Medical Record (EMR), including reports of EGD or pathology 1. M (Mucosa (mucosal invasion)): Medical data of early gastric cancer patients with confirmed Mucosa for the depth of invasion category in the EMR. 2. SM (Submucosa (submucosal invasion)): Medical data of early gastric cancer patients with confirmed Submucosa for the depth of invasion category in the EMR.

Exclusion criteria

1. Absence of pathological results for the lesion 2. History of gastrectomy 3. Judged as inappropriate for inclusion by the investigator

Design outcomes

Primary

MeasureTime frameDescription
Clinical Sensitivity in classifying early gastric cancer (EGC) based on the depth of invasion (%)3 monthsThe probability of being classified as Mucosa (mucosal invasion), based on the depth of invasion categories for early gastric cancer, among gastro-endoscopic images confirmed as Mucosa through the results of pathologic examination.
Clinical Specificity in classifying early gastric cancer (EGC) based on the depth of invasion (%)3 monthsThe probability of being classified as Submucosa (submucosal invasion), based on the depth of invasion categories for early gastric cancer, among gastro-endoscopic images confirmed as Submucosa through the results of pathologic examination.

Secondary

MeasureTime frameDescription
Accuracy in classifying the depth of invasion categories (Mucosa or Submucosa) for early gastric cancer (%)3 monthsThe probability of accurately classifying all early gastric cancer images as either Mucosa or Submucosa, based on the depth of invasion categories confirmed through pathological examination.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026